LONDON (Reuters) – Roche (ROG.S) is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker’s older cancer medicines start to grab business next year, its chief executive said on Wednesday.
In February the company won U.S. Food and Drug Administration (FDA) breakthrough status for new multiple sclerosis drug Ocrevus.
That was followed in May by U.S. approval of immuno-oncology drug Tecentriq for bladder cancer, with an expected sign-off for lung cancer waiting in the wings.
Read the entire article here.